OncoMatch/Clinical Trials/NCT04540692
Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer
Is NCT04540692 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Docetaxel or Paclitaxel and Cyclophosphamide + Doxorrubicin for breast cancer.
Treatment: Docetaxel or Paclitaxel · Cyclophosphamide + Doxorrubicin — Phase III randomized clinical trial evaluating the sequencing of anthracyclines and taxanes in neoadjuvant therapy for locally advanced HER2-negative breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) wild-type
HER-2 negative
Disease stage
Required: Stage III (RH POSITIVE), IIB/III (RH NEGATIVE) (TNM 8th edition)
Invasive breast carcinoma stage III (RH positive) or IIB/III (RH negative), according to TNM 8th edition
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
adequate organic function
Kidney function
adequate organic function
Liver function
adequate organic function
Cardiac function
adequate cardiac function as assessed by echocardiogram or MUGA
Have adequate organic function. The samples must be collected within 60 days before the start of the study treatment; Have adequate cardiac function as assessed by echocardiogram or MUGA performed up to 60 days before the start of treatment under study.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify